These results, combined with those of VCAM-1 and PAI-1, could suggest that a longer period of administration may be necessary to have an effect on circulating biomarkers of oxidative stress and endothelial dysfunction in untreated subjects with mild cardiometabolic alterations. The gene discussed is VCAM1; the disease is endothelial dysfunction.